• Angiotensin Peptides Boost Spike–Receptor Binding

  2026-09-23

  Oliveira and colleagues report that several naturally occurring angiotensin peptides increase antibody-detected binding between SARS-CoV-2 spike protein and host receptors, with the strongest reported effect for angiotensin IV. The results identify peptide sequence and modification as variables for receptor-binding assays, but do not establish that these effects increase viral infection or alter COVID-19 outcomes.

• Intravesical p21 mRNA-LNP Therapy in Bladder Cancer

  2026-09-23

  The reference study develops chemically modified CDKN1A/p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. Its cell and orthotopic mouse data support tumor-suppressor replacement as a nonviral approach that restores nuclear p21, restrains cell-cycle signaling, and limits systemic exposure.

• DiscoveryProbe FDA-Approved Drug Library: Mechanistic HTS

  2026-09-22

  Explore how the DiscoveryProbe FDA-approved Drug Library converts broad pharmacology into mechanism-aware screening decisions. This guide connects the collection to assay design, ICOS/ICOSL research, drug repositioning screening, and translational validation.

• Radiation-Altered Neuronal Differentiation via mGluR1

  2026-09-22

  Eom et al. showed that ionizing radiation does more than reduce neural stem-cell viability: it promotes an altered neuronal differentiation program in C17.2 cells through PI3K-STAT3-mGluR1 and PI3K-p53 signaling. The study combines morphology, neuronal marker analysis, receptor-gene profiling, pathway inhibition, and primary neural stem-cell validation to connect radiation exposure with potentially dysfunctional neuronal maturation.

• LGK-974: A Mechanistic Wnt Assay Tool

  2026-09-21

  LGK-974 is a potent PORCN inhibitor for dissecting ligand-dependent Wnt signaling in cancer models. This article connects its assay utility with recent pancreatic cancer findings and shows how to distinguish extracellular Wnt dependence from downstream pathway activation.

• Shufeng Xingbi Therapy in Allergic Rhinitis Rats

  2026-09-21

  This bioRxiv preprint examines how Shufeng Xingbi Therapy affects allergic rhinitis in rats through coordinated changes in nasal inflammation, Th1/Th2-associated signaling, intestinal microbiota, and short-chain fatty acids. Its integrated gut–nose experimental framework is informative for mechanism generation, although the findings remain preclinical and do not establish microbiota-mediated causality.

• DiscoveryProbe FDA-approved Drug Library for HDT

  2026-09-20

  Explore how the DiscoveryProbe FDA-approved Drug Library supports host-directed therapy, drug repositioning screening, and mechanism-aware phenotypic assays. This guide translates evidence from loperamide research into practical decisions for infection, cancer, and neurobiology workflows.

• SAG Workflows for Hedgehog Signaling Research

  2026-09-19

  Build cleaner Hedgehog pathway activation assays with SAG, a downstream Smoothened receptor agonist that separates receptor signaling from ligand presentation. This guide connects cell-based pathway rescue, mitochondrial studies, developmental models, and troubleshooting to practical experimental decisions.

• Phenacetin as a Translational Assay Benchmark

  2026-09-18

  Phenacetin can serve as a carefully controlled analytical and exposure benchmark in pharmacokinetic studies, but its safety profile demands disciplined interpretation. This article connects its physicochemical properties with the assay-design lessons of a landmark PDK4 inhibitor study, offering a framework distinct from routine organoid protocols.

• 3-Aminobenzamide: A Translational PARP Lens

  2026-09-18

  A thought-leadership guide to using 3-Aminobenzamide (PARP-IN-1) as a mechanistic probe across oxidative injury, vascular biology, diabetic nephropathy research, and PARP-linked antiviral immunity—while keeping evidence boundaries explicit.

• FXR–KLF11 Signaling in Contrast-Induced Kidney Injury

  2026-09-17

  The reference study identifies an FXR–KLF11 transcriptional axis that protects against contrast-induced acute kidney injury by suppressing JAK2/STAT3-driven inflammation and apoptosis. Its combination of an iohexol mouse model, HK-2 cell experiments, RNA sequencing, promoter assays, and genetic loss-of-function controls provides a mechanistic framework for evaluating prophylactic strategies in high-risk contrast exposure.

• Ginsenoside Rg1 Restores the Gut–Immune–Brain Axis

  2026-09-17

  This mouse study shows that Ginsenoside Rg1 mitigates behavioral, inflammatory, synaptic, and intestinal abnormalities caused by prolonged isoflurane anesthesia. Its strongest mechanistic contribution is evidence that regulatory T cells are required for restoring gut–immune–brain communication, although translation beyond this anesthesia model remains to be established.

• GS-441524: From Conversion to Quantitative Assay

  2026-09-16

  GS-441524 research is moving beyond simple compound testing toward matrix-aware measurement of prodrug conversion, exposure, and intracellular activation. This evidence-focused guide explains how LC–MS/MS findings can improve GS-441524 antiviral research, pharmacokinetic interpretation, and assay design.

• Cisapride for iPSC Cardiotoxicity Screening

  2026-09-16

  Cisapride (R 51619) is a dual-purpose research probe for connecting 5-HT4 receptor signaling with hERG-related electrophysiological risk. This workflow positions it as a practical positive-control candidate for iPSC-cardiomyocyte imaging, deep-learning phenotyping, and orthogonal cardiac validation.

• N1-Methylpseudouridine in CRISPRa Workflows

  2026-09-15

  N1-Methylpseudouridine can strengthen mRNA translation enhancement workflows when CRISPRa is used to expose splice-altering variants in accessible cells. This practical guide connects nucleotide chemistry, dCas9-VPR mRNA delivery, transcript analysis, and troubleshooting without treating a promising extension as an established diagnostic assay.

8058 records 1/538 page Next 12345 下5页 Last page